Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 2:24pm
RE:RE:RE:RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
Regarding regulation of the immune response, the BET proteins are essential for the transcription of several inflammation-related genes and have therefore been targets of interest in drug development
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 2:02pm
RE:RE:RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
October 29, 2024 - Novartis recently recorded an $800 million impairment on its MorphoSys acquisition, just five months after closing the $2.9 billion deal.
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 1:50pm
RE:RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
https://www.fiercebiotech.com/biotech/after-incytes-commercial-buy-novartis-shells-out-eu27b-newly-re-clinical-morphosys
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 1:46pm
RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
November 21, 2023 - MorphoSys CEO Jean-Paul Kress’ words are coming back to haunt him. The MorphoSys CEO has previously said AbbVie “failed” its phase 3 myelofibrosis trial because the Big
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 1:39pm
RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
Despite handing over 2.7 billion euros ($2.9 billion) cash to buy out the German biotech in February, the star of the show in Novartis’ eyes was always pelabresib, according to deal-related&
...more
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Oct 29, 2024 1:30pm
Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
October 29, 2024 - Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Oct 29, 2024 1:13pm
RE:3rd quarter
Yes, last year the 3rd quarter report & update was Nov 3rd. They issued a N.R. October 20th ( talking last year), to announce the upcoming quarterly review. Looking back histroically, they have
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Oct 29, 2024 12:33pm
RE:RE:New podcast today
thanks for the recent links. I took the time to read the first publiction. and also listen to the interview. Irecomend , the interview. As the interview does a god job of expaining various medical
...more
(114)
•••
spesestsemper
X
View Profile
View Bullboard History
Comment by
spesestsemper
on Oct 28, 2024 8:12pm
RE:New podcast today
You dont have to subscribe - just hit the play button . Only thing he mentions different is they are looking at earlier stage breast cancer .
(114)
•••
spesestsemper
X
View Profile
View Bullboard History
Post by
spesestsemper
on Oct 28, 2024 8:00pm
New podcast today
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 28, 2024 5:18pm
RE:RE:How does Accelerated Approval work
https://finance.yahoo.com/news/oncolytics-targets-accelerated-approval-oncolytic-143358596.html
(5329)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 28, 2024 5:16pm
RE:How does Accelerated Approval work
ONCY is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II breast cancer trial. https://www.clinicaltrialsarena.com/news/oncolytics
...more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Oct 28, 2024 5:08pm
RE:RE:3rd quarter
There are plenty of other sites where you can express your political views... this site is reserved for .... for... heck I'm not even sure what is site is reserved for... wishing and hoping run
...more
(114)
•••
spesestsemper
X
View Profile
View Bullboard History
Post by
spesestsemper
on Oct 28, 2024 11:16am
3rd quarter
My account shows third quarter results on November 1st . Its strange in that they usually have a news release about a week in advance of the conference call . Can anyone confirm the november 1st date
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden